Steven Gillis joins Shire board
This article was originally published in Scrip
Shire has elected Dr Steven Gillis to its board of directors, effective from 1 October 2012. Dr Gillis is currently managing director at ARCH Venture Partners, where he is focused on the evaluation of new life sciences technologies and the development and growth of ARCH's biotech portfolio companies. He is also a non-executive director of Genesis Research and Development Corporation.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.